All In MedTech

FDA Clearance Tracker · P910023

CADENCE(R) TIERED THERAPY DEFIBRILLATION SYSTEM

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Apr 30, 1993 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Apr 30, 1993

Approved

Time to decision

738 days

Received Apr 23, 1991. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P910023
Device name
CADENCE(R) TIERED THERAPY DEFIBRILLATION SYSTEM
Applicant location
Sylmar, CA
Received
Apr 23, 1991
Decided
Apr 30, 1993
Decision
Approved
Supplements
461 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code LWS

FDA's approval statement

As written in FDA's record.

Approval for the Cadence® Tiered Therapy Defibrillator System. This device is indicated for use in patients with a history of hemodynamically compromising ventricular tachyarrhythmias. These patients may have experienced a cardiac arrest not associated with acute myocardial infarction or have ventricular tacharrhythmias. In addition, the Cadence® can be used in patients whose primary therapy for hemodynamically significant, sustained ventricular tachycardia is antitachycardia pacing; the defibrillation capabilities of the device provide high energy therapy in the event that the arrhythmia accelerates. The Cadence® is intended for use with the defibrillation lead systems with which it has been tested: Ventritex epicardial defibrillation leads, and commercially available CPI defibrillation patch leads and superior vena cava (SVC) spring leads. When used with the CPI patch lead or SVC leads, the Cadence® is intended for use as a replacement for CPI automatic implantable cardioverter defibrillators.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code LWS. The earliest in FDA's data is P830060, decided Oct 4, 1985.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for ABBOTT MEDICAL

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.